PGGM Investments Has $23.15 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PGGM Investments boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 32,497 shares of the biopharmaceutical company’s stock after buying an additional 6,300 shares during the quarter. PGGM Investments’ holdings in Regeneron Pharmaceuticals were worth $23,149,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $26,000. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Private Wealth Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 4.0 %

Shares of Regeneron Pharmaceuticals stock opened at $689.50 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a market capitalization of $75.38 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 2.34 and a beta of 0.27. The firm’s 50-day moving average price is $696.62 and its two-hundred day moving average price is $841.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on REGN. Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Finally, Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.